For research use only. Not for therapeutic Use.
ATV399（Cat No.:I022643）is a small molecule inhibitor targeting the protein kinase STK19 (serine/threonine kinase 19), which plays a role in regulating various cellular functions, including cell cycle progression and apoptosis. STK19 is implicated in the development of certain cancers, particularly in regulating the survival and proliferation of tumor cells. By inhibiting STK19, ATV399 aims to reduce cancer cell growth and enhance the effectiveness of other cancer treatments. Preclinical studies are investigating its potential in treating various cancers, including solid tumors and hematological malignancies, with further clinical trials needed to assess its safety and therapeutic efficacy.
| Catalog Number | I022643 |
| CAS Number | 393834-37-2 |
| Synonyms | ATV-399; ATV 399; ATV399 |
| Molecular Formula | C24H23N3O5S |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | N-[4-(2-pyridin-3-ylpiperidin-1-yl)sulfonylphenyl]-1,3-benzodioxole-5-carboxamide |
| InChI | InChI=1S/C24H23N3O5S/c28-24(17-6-11-22-23(14-17)32-16-31-22)26-19-7-9-20(10-8-19)33(29,30)27-13-2-1-5-21(27)18-4-3-12-25-15-18/h3-4,6-12,14-15,21H,1-2,5,13,16H2,(H,26,28) |
| InChIKey | JLXWVIUZQVTKNB-UHFFFAOYSA-N |
| SMILES | C1CCN(C(C1)C2=CN=CC=C2)S(=O)(=O)C3=CC=C(C=C3)NC(=O)C4=CC5=C(C=C4)OCO5 |
| Reference | 1: Zhong L, Tran T, Baguley TD, Lee SJ, Henke A, To A, Li S, Yu S, Grieco FA, Roland J, Schultz PG, Eizirik DL, Rogers N, Chartterjee AK, Tremblay MS, Shen W. A novel inhibitor of inducible NOS dimerization protects against cytokine-induced rat beta cell dysfunction. Br J Pharmacol. 2018 Sep;175(17):3470-3485. doi: 10.1111/bph.14388. Epub 2018 Jul 14. PubMed PMID: 29888783; PubMed Central PMCID: PMC6086989. |
